Sipuleucel-T is a dendritic cell (DC)-based immunotherapy that is designed to stimulate immune response to prostatic acid phosphatase (PAP) which has been demonstrated to be specific for prostate tissue and most of prostate carcinomas [150]. This evidence concerns the gene ACP3 and prostate carcinoma.